- Home
- NUVB vs PRAX Comparison
NUVB vs PRAX Comparison
Compare NUVB & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- PRAX
- Stock Information
- Founded
- NUVB 2018
- PRAX 2015
- Country
- NUVB United States
- PRAX United States
- Employees
- NUVB N/A
- PRAX N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- NUVB Health Care
- PRAX Health Care
- Exchange
- NUVB Nasdaq
- PRAX Nasdaq
- Market Cap
- NUVB 1.1B
- PRAX 950.8M
- IPO Year
- NUVB N/A
- PRAX 2020
- Fundamental
- Price
- NUVB $3.28
- PRAX $44.03
- Analyst Decision
- NUVB Strong Buy
- PRAX Strong Buy
- Analyst Count
- NUVB 6
- PRAX 9
- Target Price
- NUVB $8.17
- PRAX $94.44
- AVG Volume (30 Days)
- NUVB 6.7M
- PRAX 383.5K
- Earning Date
- NUVB 11-05-2025
- PRAX 11-05-2025
- Dividend Yield
- NUVB N/A
- PRAX N/A
- EPS Growth
- NUVB N/A
- PRAX N/A
- EPS
- NUVB N/A
- PRAX N/A
- Revenue
- NUVB $14,355,000.00
- PRAX $7,765,000.00
- Revenue This Year
- NUVB $332.80
- PRAX N/A
- Revenue Next Year
- NUVB $360.12
- PRAX $22.22
- P/E Ratio
- NUVB N/A
- PRAX N/A
- Revenue Growth
- NUVB 900.35
- PRAX 338.45
- 52 Week Low
- NUVB $1.54
- PRAX $26.70
- 52 Week High
- NUVB $4.09
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- NUVB 58.18
- PRAX 48.77
- Support Level
- NUVB $3.20
- PRAX $37.25
- Resistance Level
- NUVB $3.41
- PRAX $40.69
- Average True Range (ATR)
- NUVB 0.27
- PRAX 2.54
- MACD
- NUVB -0.03
- PRAX -0.03
- Stochastic Oscillator
- NUVB 33.55
- PRAX 61.04
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.